The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER
 
Paolo Ciracì
No Relationships to Disclose
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Marco Maria Germani
No Relationships to Disclose
 
Adele Busico
No Relationships to Disclose
 
Paolo Manca
No Relationships to Disclose
 
Gianmarco Ricagno
No Relationships to Disclose
 
Nicoletta Pella
No Relationships to Disclose
 
Vincenzo Formica
Honoraria - Amgen; Merck Serono; MSD; Pierre Fabre; SERVIER
 
Mario Scartozzi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Sanofi; GlaxoSmithKline; Merck; MSD; Rottapharm Biotech; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Sanofi; GlaxoSmithKline; Merck; MSD; SERVIER
Research Funding - Sanofi
Travel, Accommodations, Expenses - Merck; MSD; SERVIER
 
Valentina Burgio
No Relationships to Disclose
 
Samantha Di Donato
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Bayer
 
Roberto Moretto
No Relationships to Disclose
 
Iolanda Capone
No Relationships to Disclose
 
Federica Palermo
No Relationships to Disclose
 
Federica Marmorino
No Relationships to Disclose
 
Gianluca Masi
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology; Roche; Roche; TERUMO
Research Funding - Terumo (Inst); Terumo (Inst)
Patents, Royalties, Other Intellectual Property - Terumo (Inst)
 
Luca Boni
Consulting or Advisory Role - Pfizer
Patents, Royalties, Other Intellectual Property - International Patent nr. PCT/EP2012/065661
 
Daniele Rossini
Speakers' Bureau - Amgen; Bayer; MSD; Pierre Fabre; Takeda